PhRMA member companies ’ R & D investments reach record high of $91.1 billion in 2020

PhRMA member companies ’ robust investment in research and development (R&D) has led to advances and discoveries that are transforming health care and our approach to treating patients for a broad range of chronic and rare conditions, as well as urgent new health challenges like COVID-19.
Source: The Catalyst - Category: Pharmaceuticals Authors: Tags: Research and Development Economic Impact PhRMA Member Company Source Type: news